Clinical Report: Corrections Noted in Tables 2 and 3

Overview

This report addresses corrections made to Tables 2 and 3 in the original investigation regarding artificial intelligence-detected tumor-infiltrating lymphocytes in melanoma. The corrections involve changes in statistical measures for progression-free survival, overall survival, and overall response rate.

Background

Accurate data presentation is crucial in clinical research, particularly in studies involving treatment outcomes for melanoma, a condition where anti-PD-1 therapies are standard. Errors in published tables can lead to misinterpretation of results, impacting clinical decision-making and patient care.

Data Highlights

Corrections made to statistical measures in Tables 2 and 3 include:

Key Findings

• Table 2's univariable column now correctly lists hazard ratios for progression-free survival and overall survival.
• Table 2's multivariable column now correctly lists odds ratios for overall response rate.
• Table 3's measures for progression-free survival have been corrected to hazard ratios.
• Two rows were missing in the original Table 2, which have now been included.
• These corrections ensure accurate representation of the study's findings on tumor-infiltrating lymphocytes and treatment outcomes.

Clinical Implications

Clinicians should be aware of these corrections to ensure they are referencing accurate data when considering treatment options for melanoma patients. Continuous updates and corrections in clinical literature highlight the importance of vigilance in data interpretation.

Conclusion

Highlight the broader implications of maintaining data integrity in clinical research.

Related Resources & Content

1. Erratum: Outcomes of Isokinetic and Functional Shoulder Assessment Following Arthroscopic Capsulolabral Stabilization, Archives of Orthopaedic and Trauma Surgery, 2021 -- Correction to: Outcomes of Isokinetic and Functional Shoulder Assessment Following Arthroscopic Capsulolabral Stabilization
2. Gastric Cancer — Correction to: Significance of Fixation Conditions for HER2 Assessment in Gastric Cancer: Immunohistochemical Analysis and Fluorescence In Situ Hybridization, Gastric Cancer, 2014
3. Erratum: Comparing the 'true' acetabular anteversion angle (AV angle) using 2D CT and 3D modeling techniques, International Journal of Computer Assisted Radiology and Surgery, 2022
4. NCCN GUIDELINES® INSIGHTS Melanoma: Cutaneous, Journal of the National Comprehensive Cancer Network, 2024
5. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update, PubMed, 2025
6. Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma, JAMA Oncology, 2025
7. Journal of Neuro-Oncology — Amendment to: Pediatric Central Nervous System Tumors in Patients Aged Under 5: Insights on Treatment Challenges, Survival Rates, and Long-Term Outcomes
8. CE NCCN GUIDELINES® INSIGHTS Melanoma: Cutaneous,
9. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update - PubMed
10. Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma | Cancer Biomarkers | JAMA Oncology | JAMA Network